chlorphenesin
Trade name: maolate
Small moleculeapproved
Approved
Jun 14, 1965
Chlorphenesin carbamate (Maolate, Musil) is a centrally acting muscle relaxant used to treat muscle pain and spasms. Сhlorphenesin acts in the central nervous system (CNS) rather than directly on skeletal muscle. It also has antifungal and some antibacterial properties. The major adverse effects are drowsiness and dizziness. — NCATS
Clinical trial activity
1 trials · 3 clinical orgs · 2 marketing orgs
Phase 1
1
Phase 2
0
Phase 3
0
Phase 4
0
Earliest trial started Nov 30, 2021 (NCT05083780)
Timeline
Indications
Studied for
Mechanism of action
- Unspecified targetOTHER
Unknown
Approval history
- approvedJun 14, 1965
Chemistry & pharmacology
Loading structure…
SMILES
NC(=O)OCC(O)COC1=CC=C(Cl)C=C1- Mol. weight
- 245.66 g/mol
- Lipinski Ro5
- Pass
- Rule of 3
- No
- Chirality
- Racemic Mixture
- Inorganic
- No
- Polymer
- No
- Delivery
- Oral
- Availability
- Discontinued
Oral
Yes
Parenteral
No
Topical
No
Sources
- WikipediaChlorphenesin carbamate ↗
- NCATS57U5YI11WP ↗
- ChEMBLCHEMBL607710 ↗
Also known as
- 3-(4-chlorophenoxy)-1,2-propanediol
- 3-(4-chlorophenoxy)-1,2-propanediol
- 3-(p-chlorophenoxy)-1,2-propanediol
- 3-(p-chlorophenoxy)-1,2-propanediol
- 3-(p-chlorophenoxy)propane-1,2-diol
- 3-(p-chlorophenoxy)propane-1,2-diol
- chlorphenesin
- chlorphenesin
- chlorphenesin
- chlorphenesin
- chlorphenesin
- chlorphenesin carbamate
- chlorphenesin carbamate
- chlorphenesin carbamate
- chlorphenesin carbamate
- chlorphenesin carbamate
- chlorphenesin carbamate
- chlorphenesin carbamate
- chlorphenesin carbamate
- chlorphenesin carbamate
- chlorphenesin carbamate
- chlorphénésine
- chlorphénésine
- chlorphenesinum
- chlorphenesinum
- chlorphensin carbamate
- clorfenesina
- clorfenesina
- glycerol alpha-p-chlorophenyl ether
- glycerol alpha-p-chlorophenyl ether
- maolate
- maolate
- maolate
- maolate
- p-chlorophenyl-alpha-glyceryl ether
- p-chlorophenyl-alpha-glyceryl ether
- u-19646
- u-19646
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT05083780 | Phase 1 | Nov 30, 2021 | Cytogen, ONCOCROSS Co., Ltd., University of Ulsan |
Showing 1 of 1 trials
Page 1 / 1
Organizations
Research & Development (3)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Cytogen | For profit | 1 | 0 | 1 | 2021 |
| ONCOCROSS Co., Ltd. | For profit | 1 | 0 | 1 | 2021 |
| University of Ulsan | Academic/Hospital | 1 | 1 | 1 | 2021 |
3 organizations
Page 1 / 1